Safety and Tolerability of TAR-302-5018 in Subjects With Neurogenic Detrusor Overactivity Resulting From Spinal Cord Injury

NCT ID: NCT03168828

Last Updated: 2020-01-13

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 7 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2017-04-24
• Study Completion Date: 2018-07-26

Brief Summary

The purpose of this study is to determine if TAR-302-5018, an investigational drug-delivery system, is safe and tolerable in patients with neurogenic detrusor overactivity (NDO) resulting from spinal cord injury (SCI).

Conditions

Neurogenic Detrusor Overactivity

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

TAR-302-5018

Trospium-Releasing Intravesical System (TAR-302-5018) is placed into the bladder through an inserter on Study Day 0 and is removed on Study Day 42. TAR-302-5018 releases trospium gradually during the 42 day indwelling time.

Group Type: EXPERIMENTAL

Trospium-Releasing Intravesical System (TAR-302-5018)

Intervention Type: DRUG

TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.

Interventions

Trospium-Releasing Intravesical System (TAR-302-5018)

TAR-302-5018 is a passive, nonresorbable trospium-releasing intravesical system whose primary mode of action is the controlled release of trospium into the bladder over a 42-day period.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

1. Diagnosis of traumatic or nontraumatic suprasacral SCI for longer than 6 months and a documented history of NDO.

2. Age ≥ 18 years.

3. Demonstrated competence in and currently uses intermittent catheterization (IC) to empty the bladder (minimum of 4 IC events/day).

• No indwelling catheter permitted
• Caregiver may perform IC
• Subject must be willing to maintain an established IC frequency throughout the study

4. History of non-stress-based urinary incontinence.

Exclusion Criteria

1. Participation in another drug or device study within 60 days prior to the screening visit.

2. Previous urologic surgery that either decreases outlet resistance (transurethral prostatectomy, urethral stent, sphincterotomy) or changes native bladder anatomy (bladder augmentation).

3. Presence of significant renal dysfunction at screening (Glomerular Filtration Rate < 30 mL/min).

4. Presence of significant polyuria of any cause at screening (urine output > 4,000 mL/day).

5. History of pelvic radiation.

6. History of either bladder cancer or bladder pathology that the investigator deems unfit for study inclusion.

7. Active malignancies within 12 months with the exception of those with a negligible risk of metastasis or death treated with expected curative outcome.

8. Symptomatic autonomic dysreflexia requiring ongoing treatment.

9. In the opinion of the investigator, the subject has a history of significant stress urinary incontinence.

10. Subjects with active bladder stones or history of bladder stones < 6 months prior to study entry.

11. History of recurrent symptomatic UTIs (> 6 per 1 year).

12. Subjects with either untreated urinary retention or gastric retention or uncontrolled narrow-angle glaucoma.

13. Subjects with known hypersensitivity to trospium or chemically-related drugs.

14. Subjects with known hypersensitivity to nitinol or silicone.

15. Subjects actively taking oral trospium. If previously used and discontinued, these medications must have been stopped for >2 weeks.

16. The addition of a new or a change in dose to a current medication for the treatment of OAB (i.e. anticholinergics, beta-3 adrenergic agonists, antispasmodics, antidepressants, or hormones) within 30 days prior to signing the Informed Consent Form (ICF). A current dose must continue through the final study visit. If previously used and discontinued, these medications must have been stopped for > 2 weeks prior to Day 0.

17. Intravesical onabotulinum toxin use within the last 9 months prior to the screening visit.

18. Intravesical anticholinergic medications within the last 30 days prior to the screening visit.

19. History of non-medication based therapy (i.e. Interstim therapy) for the treatment of OAB. History of non-invasive neuromodulation (i.e. Percutaneous Tibial Nerve Stimulation (PTNS)) is allowed if discontinued at least 8 weeks prior to Study Day 0.

20. Female subject who is pregnant (as verified by urine test at time of screening) or lactating or of childbearing potential and not using acceptable methods of contraception.

21. Subject has a medical condition that may cause noncompliance with the study protocol.

22. Subject refuses to provide written informed consent.

23. Subject will be unable or unwilling to complete the questionnaires, diaries, or attend all protocol mandated study visits.

24. Presence of any bladder or urethral anatomic feature that in the opinion of the investigator may prevent the safe placement, indwelling use or removal of TAR-302-5018.

25. History or presence of any significant cardiovascular, pulmonary, hepatic, renal, gastrointestinal, gynecological, endocrine, immunological, dermatological, neurological or psychiatric disease or disorder that, in the opinion of the investigator, contraindicates participation.

26. History of any of the following within 3 months prior to Screening Visit:

1. Major illness/major surgery (requiring hospitalization), including pelvic, lower back surgery or procedure unrelated to bladder cancer; most outpatient procedures are not exclusionary

2. Renal or ureteral stone disease or instrumentation

3. Childbirth

27. Difficulty providing blood samples.

28. Other unspecified reasons that, in the opinion of the investigator or TARIS, make the subject unsuitable for enrollment.

• Minimum Eligible Age: 18 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Taris Biomedical LLC

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Michael Kennelly, MD

Role: PRINCIPAL_INVESTIGATOR

Wake Forest University Health Sciences

Locations

Michigan Institute of Urology

Troy, Michigan, United States

Carolinas HealthCare System

Charlotte, North Carolina, United States

Urology of Virginia

Virginia Beach, Virginia, United States

Virginia Mason

Seattle, Washington, United States

Countries

United States

Other Identifiers

TAR-302-101

Identifier Type: -

Identifier Source: org_study_id